Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

244.39 -0.16 (-0.07%)
Streaming Delayed Price Updated: 2:31 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Disney's Big Breakup? Wall Street, Iger Ponder A Magical Split
Disney is facing decisions about a potential split, with a focus on core businesses like streaming, parks, and film studios. CEO Bob Iger remains noncommittal. 
Via MarketBeat
Topics Earnings
News headline image
Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson (NYSE: JNJ) is One of Monday Morning’s Most Active Stocks
Via Investor Brand Network
Johnson & Johnson (NYSE: JNJ) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
Johnson & Johnson (NYSE: JNJ) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer
From Johnson & Johnson
Via Business Wire
News headline image
Antiepileptic Drugs Market to Witness Massive Growth by 2028 : Johnson & Johnson, Sumitomo Pharma, Sanofi ↗
Stay up to date with Antiepileptic Drugs Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
News headline image
Johnson & Johnson Announces Final Exchange Ratio of 8.0324 in Split-Off of Kenvue Inc.
From Johnson & Johnson
Via Business Wire
News headline image
5 Best Stocks to Buy in a Bear Market
Want income-producing assets and stable stocks? Look for stocks with stable cash flow in rock-solid industries for the best stocks to buy in a bear market. 
Via MarketBeat
Topics Economy
News headline image
3 Stocks to Play the Recovery in Digital Advertising
The slowdown in digital advertising triggered many technology stocks to sell off, notably social media platforms like Snap Inc. (NASDAQ: SNAP). However, a 
Via MarketBeat
Topics Earnings
News headline image
Johnson & Johnson to Participate in the 2023 Wells Fargo Securities Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
Rising Dividend Make Zoetis a Doggone Winner
Investors that typically focus on other large cap pharmaceutical plays may wish to consider an alternative bet on pets with shares of Zoetis. 
Via MarketBeat
News headline image
Nachawati Law Group Trial Lawyers Renew Commitment to Cancer Victims After Judge’s Rejection of Johnson & Johnson’s Proposed $8.9B Settlement
From Nachawati Law Group
Via Business Wire
News headline image
3 Consumer Discretionary Stocks That Still Have Pricing Power
Pricing power fuels earnings growth and here are three consumer discretionary stocks that have recently given investors confirmation of their pricing power 
Via MarketBeat
Topics Economy
News headline image
Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement
From Kenvue Inc.
Via Business Wire
News headline image
Johnson & Johnson Launches Exchange Offer for Separation of Kenvue Inc.
From Johnson & Johnson
Via Business Wire
News headline image
MarketBeat Week in Review – 7/17 - 7/21
Investor sentiment remains strong but upcoming tech earnings and an expected interest rate hike may provide more clarity on the short-term outlook for stocks 
Via MarketBeat
Topics Economy
News headline image
Johnson & Johnson's Inflection Point: What it Means for Investors
Johnson & Johnson stock and the company show signs of strength and growth while offering value and yield relative to its peer Abbott Laboratories. 
Via MarketBeat
News headline image
Johnson & Johnson Reports Q2 2023 Results
From Johnson & Johnson
Via Business Wire
News headline image
Investing in Blue Chip Stocks: A Guide to Stability and Growth
Learn how to identify and evaluate blue chip stocks, why they are a reliable investment, and how to incorporate them into your portfolio for long-term success. 
Via MarketBeat
News headline image
Johnson & Johnson to Participate in the UBS MedTech, Tools and Genomics Summit
From Johnson & Johnson
Via Business Wire
News headline image
Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy
Inspire Medical Systems has surged nearly 15% since its breakout, driven by positive Q1 results and FDA approvals. Analysts have a "buy" rating on the stock. 
Via MarketBeat
News headline image
OnderLaw Lauds Revolutionary Drug Combination that Offers Hope for Women with Ovarian Cancer
June 23, 2023 -- Drug Combination Shows Special Promise to Those Diagnosed with Johnson & Johnson Talc-Related Ovarian Cancer 
Via 24-7 Press Release
News headline image
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer. 
Via MarketBeat
News headline image
Will Cava's Successful Debut Raise Hope For Reviving IPO Market?
Cava's strong IPO performance suggests a warming trend in the market for new public debuts. However, several eagerly anticipated offerings remain on hold. 
Via MarketBeat
Topics Initial Public Offering
Filariasis Market and Epidemiology 2032: Treatment Market, Therapies, FDA Approvals, and Companies by DelveInsight | Johnson & Johnson, Pfizer, Eisai Co Ltd, Atra Pharmaceuticals, AbbVie, Novartis
Via AB Newswire
Ophthalmoplegia Market expected to rise | Companies – Abbott, Novartis AG, ZEISS International, Valeant Pharmaceuticals International, ALLERGAN, Johnson & Johnson, expected to drive market
Via AB Newswire
News headline image
2022 R&D Spending and Intensity Benchmarks
VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D... 
Via PRLog
Topics Supply Chain
News headline image
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.